Effects of Losartan on Hepatic Fibrogenesis in Chronic Hepatitis C

This study has been completed.
Information provided by:
Hospital Clinic of Barcelona
ClinicalTrials.gov Identifier:
First received: March 2, 2006
Last updated: November 21, 2007
Last verified: November 2007

There is evidence on the beneficial effects of the administration of angiotensin II type 1 (AT1) receptors antagonists on liver fibrosis in hepatic stellate cells, experimental models of liver fibrosis in rodents and limited information in chronic hepatitis C with mild fibrosis.

The purpose of this study is to investigate the effect of long-term administration of oral Losartan, an AT1 receptor antagonist, on liver fibrogenesis in patients with chronic hepatitis C and fibrosis F2-F3 (METAVIR score).

Condition Intervention Phase
Chronic Hepatitis C
Liver Fibrosis
Drug: Losartan
Phase 4

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Effect of Long-Term Administration of Oral Losartan on Hepatic Fibrogenesis and Gene Expression in Chronic Hepatitis C With Significant Liver Fibrosis.

Resource links provided by NLM:

Further study details as provided by Hospital Clinic of Barcelona:

Primary Outcome Measures:
  • Assessment of liver fibrogenesis by changes in gene expression of key mediators of liver fibrosis.

Estimated Enrollment: 20
Study Start Date: March 2003
Study Completion Date: January 2006

Ages Eligible for Study:   35 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • age between 35 and 65 years
  • chronic hepatitis C with intermediate fibrosis (F2-F3 in Metavir score).
  • non-responder or contraindication to antiviral therapy.

Exclusion Criteria:

  • any other cause of liver disease
  • HIV positive
  • alcohol consumption
  • arterial hypertension
  • creatinine > 1.5mg/dL
  • treatment with AT1 receptor antagonists or angiotensin converting enzyme inhibitors in the past 12 months.
  • antiviral therapy in the past 12 months
  • contraindications to oral losartan
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00298714

Sponsors and Collaborators
Hospital Clinic of Barcelona
Principal Investigator: Pere Ginès, M.D. Liver Unit, Institut Clínic de Malalties Digestives, Hospital Clínic, Barcelona
Study Chair: Vicente Arroyo, M.D. Liver Unit, Institut Clínic de Malalties Digestives, Hospital Clínic, Barcelona
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
ClinicalTrials.gov Identifier: NCT00298714     History of Changes
Other Study ID Numbers: ARAHEPC  Protocol number: 02-0491 
Study First Received: March 2, 2006
Last Updated: November 21, 2007
Health Authority: Spain: Spanish Agency of Medicines

Keywords provided by Hospital Clinic of Barcelona:
Hepatitis C, Chronic

Additional relevant MeSH terms:
Hepatitis A
Hepatitis C
Hepatitis C, Chronic
Hepatitis, Chronic
Liver Cirrhosis
Digestive System Diseases
Enterovirus Infections
Flaviviridae Infections
Hepatitis, Viral, Human
Liver Diseases
Pathologic Processes
Picornaviridae Infections
RNA Virus Infections
Virus Diseases
Angiotensin II Type 1 Receptor Blockers
Angiotensin Receptor Antagonists
Anti-Arrhythmia Agents
Antihypertensive Agents
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on May 30, 2016